N Engl J Med January 2021 PMID 33200891

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod, David Z I Cherney, Jamie P Dwyer, Benjamin M Scirica, Clifford J Bailey, Rafael Díaz

Full text PDF Download social card

Mentions

218

Peak: 87 in Jan 2021

across 5 sources since Nov 2020

Extended reach

991,101

potential audience

Total likes

491

Video views

6,752

Mentions per month

Nov 2020 – May 2025

Where it's discussed

X / Twitter167 posts
News35 articles
Blogs8 articles
YouTube4 videos
Facebook4 posts

AI synopsis

What people are saying

The overall tone reflects strong agreement and interest, with examples such as remarks on the overwhelming evidence for SGLT2 inhibitors and the benefits for kidney health, as well as praise for the trial's leadership. Words like 'benefits,' 'beneficial,' and 'delighted' emphasize enthusiasm, while detailed mentions of cardiovascular outcomes highlight the perceived high impact of the research.

AgreementModerate agreement

Most posts highlight the positive outcomes of the publication, emphasizing reduced cardiovascular risks and benefits of Sotagliflozin, suggesting general agreement with the findings.

InterestHigh interest

The discussions demonstrate high interest, with numerous references to the trial results, mechanisms, and implications for diabetes and kidney disease management.

EngagementHigh engagement

Posts include detailed evaluations, praise for the research leadership, and comments on clinical significance, indicating deep engagement with the topic.

ImpactHigh impact

The widespread sharing, enthusiasm, and emphasis on the trial's importance reflect a significant potential impact on medical practice and future research.

Abstract in brief

The study aimed to assess the effectiveness and safety of sotagliflozin, a sodium-glucose cotransporter 2 inhibitor, in preventing cardiovascular events in patients with type 2 diabetes and chronic kidney disease, though funding issues led to it being ended early.
A total of 10,584 patients were divided equally into two groups—one receiving sotagliflozin and the other a placebo—and monitored for approximately 16 months, focusing on key cardiovascular health outcomes.
Results indicated that the sotagliflozin group experienced fewer primary cardiovascular events (5.6 per 100 patient-years) compared to the placebo group (7.5 per 100 patient-years), but some adverse effects like diarrhea and infections

Read the full abstract

All mentions

Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor for Diabetes and Kidney Disease

Patients with diabetes are at high risk for heart failure and ischemic events. Sotagliflozin, approved for use in diabetes and chronic kidney disease, inhibits SGLT2 and SGLT1, reducing glucose absorption and…

pharmacy by asim · Jun 20, 2023 3,861 views

Exploring Longevity: Supplements, Drug Repurposing, and CR Insights

Longevity Science explores the impact of supplements and drug repurposing on health and aging. This video discusses how circadian alignment and caloric restriction can influence lifespan in mice, highlighting metabolic…

Dr. Laurena Law · May 28, 2025 2,025 views

Sotagliflozin: Dual SGLT Inhibitor for Diabetes Management

Sotagliflozin is a dual inhibitor targeting sodium-glucose transporters SGLT2 and SGLT1. It aids in managing type 1 and type 2 diabetes through increased glucose excretion and reduced absorption. This video explores its…

pharmacy by asim · Aug 18, 2023 842 views

Insights into Subclinical Atrial Fibrillation Progression and Detection

This week’s podcast discusses AF screening, the effects of atrial fibrillation detection, and a study on the natural history of subclinical AF detected by implantable loop recorders. Learn about the progression…

Medscape · Mar 27, 2024 24 views

kintya

@kintya2 · X

@Ryu04196650Ryu @TheLancetEndo sotaglifrozinの2019のNEJMの論文。死亡率を減らしていて良い結果。会社からのファンドが出なくなって早期終了とabstractに書いてあるのは一体… https://t.co/WIBTNVC4Mj

Feb 17, 2025 · 2 likes · 319 followers View post →

Your Pharmacists Diary

@Pharma_Diary · X

https://t.co/Wj8BwjqcLN

Jun 15, 2023 · 5,577 followers View post →

Emmanuel Espinoza

@luisemmaespin · X

RT @AmbrizMau: En pacientes con diabetes y ERC con o sin albuminuria, SOTAGLIFLOZINA resultó en menor riesgo de muertes por causas cardiova…

Jun 17, 2022 · 12 shares · 78 followers View post →

Juan Felipe Vasquez R

@JuanFeVas08 · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM Estos medicamento siguen sorprendiendo, buena presentación de en #ACC22 ⁦⁦@ACCinTouch⁩ https://t.co/5lF0fT3fWi

Apr 2, 2022 · 4 likes · 122 followers View post →

青島周一

@syuichiao89 · X

https://t.co/FRxXaEnD6X https://t.co/h3icQ74PIw どちらも一次アウトカム変更。

Oct 23, 2021 · 2 likes · 8,602 followers View post →

鯵ゼミ_Journal Club

@AJSR_since2005 · X

#055 Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease N Engl J Med 2021;384:129-39.

Sep 4, 2021 · 6 followers View post →

pinacol

@pinacol · X

RT @pinacol: 【RCT】CKDおよび心血管疾患リスクを伴う2型糖尿病患者へのSotagliflozin投与は、プラセボ投与と比較して、心血管死、心不全による入院および心不全による緊急受診を減少させた（主要評価項目を試験中に変更; 資金の喪失により早期終了）。 #ペ読…

Jul 8, 2021 · 1 share · 1,612 followers View post →

Abdallah Al-Mohammad

@AAlMohammad87 · X

#Sotagliflozin in pts with #DM_II and #CKD (eGFR 25-60ml/min/1.73msq) significantly (HR 0.74) reduces the composite end point of CV mortality, HF hospitalisation & urgent #HF visits in the #SCORED trial @NEJM @BSHeartFailure #CardioTwitter DOI: 10.1056/NEJMoa2030186 https://t.co/9Hi8yV06hE

May 18, 2021 · 3 likes · 924 followers View post →

Metabolic Health Digest

@methealthdigest · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease Read more - https://t.co/JQbfgc3iHq #metabolichealthdigest #hypertension #bloodpressure #diabetes #kidneydisease #highbloodpressure https://t.co/XNQuJIIQ6a

Apr 2, 2021 · 10 followers View post →

Irving Trejo Curiel

@irvtc · X

RT @JonathanNefro: En enfermedad renal crónica G3, diabetes y riesgo cardiovascular, SOTAGLIFLOZIN (inhibidor de SGLT-1 y 2) redujo 33% el…

Mar 29, 2021 · 13 shares · 33 followers View post →

EvidenceStock

@EvidenceStock · X

RT @q0_0_: SCORED trial@NEJM2021 腎発現SGLT2のみならず、消化管発現SGLT1も抑制するsotaglifrozinの心血管系イベント抑制効果を、糖尿病合併慢性腎臓病患者(eGFR 25-60)において評価した無作為化二重盲検試験がその有効性を…

Mar 28, 2021 · 1 share · 44 followers View post →

Yasser UMKCRCT

@ymhs92 · X

SCORED: In patients with T2D and CKD, sotagliflozin decreased deaths from CV causes, hospitalizations for HF, and urgent visits for HF compared to placebo but was associated with more dehydration, DKA, mycotic infections #UMKCRCT https://t.co/4dEAfN9T9O

Mar 14, 2021 · 10 followers View post →

El Residente

@elerre5_ · X

RT @JonathanNefro: En enfermedad renal crónica G3, diabetes y riesgo cardiovascular, SOTAGLIFLOZIN (inhibidor de SGLT-1 y 2) redujo 33% el…

Mar 11, 2021 · 13 shares · 330 followers View post →

El Residente

@elerre6_ · X

RT @JonathanNefro: En enfermedad renal crónica G3, diabetes y riesgo cardiovascular, SOTAGLIFLOZIN (inhibidor de SGLT-1 y 2) redujo 33% el…

Mar 11, 2021 · 13 shares · 329 followers View post →

Swapnil Hiremath @hswapnil.medsky.social

@hswapnil · X

@Nephro_Sparks @ChristosArgyrop @mikejohansenmd @Maratosflier @VijayanMD @Charbel_Khoury @kdjhaveri (& of course diarrhea was more in type 2 Sota trials: SCORED https://t.co/RJLC7WWQcl SOLOIST https://t.co/RG3Ifc4xqa )

Feb 14, 2021 · 2 likes · 21,701 followers View post →

Heather Morgans

@PedsKidneyDoc · X

Interesting placebo vs Sotagliflozin trail in patients with diabetes and CKD. Unfortunately, stopped early due to lack of funding. #UMKCRCT https://t.co/iZ3KsnvPk1 https://t.co/yVRQ5JCseO

Feb 4, 2021 · 39 followers View post →

Michalina Kolodziejczak

@KolodziejczakMD · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 28, 2021 · 43 shares · 23 followers View post →

McMaster Heart Function Education

@MacHeartFailure · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 28, 2021 · 13 shares · 508 followers View post →

KingstonTravel

@KTravelClinic · X

Study examines how sotagliflozin reduces the risk of cardiovascular associated deaths. https://t.co/g7nG5hj2NA

Jan 23, 2021 · 593 followers View post →

Yüksel Ürün

@DrYukselUrun · X

Sotagliflozin in Patients with #diabetes and Chronic Kidney Disease:

Jan 21, 2021 · 2 likes · 9,762 followers View post →

Ivan Velázquez

@Nephro_Ivan · X

Otro SGLT2 al arsenal terapéutico

Jan 20, 2021 · 2,340 followers View post →

Arantxa Magallón

@ArantxaMagallon · X

RT @FarmaciaHums:

Jan 20, 2021 · 3 shares · 218 followers View post →

maria jose agustin

@mariajoseaf76 · X

RT @FarmaciaHums:

Jan 19, 2021 · 3 shares · 374 followers View post →

UCI - SMed Intensiva HU Miguel Servet. Zaragoza.

@UciServet · X

RT @FarmaciaHums:

Jan 19, 2021 · 3 shares · 373 followers View post →

Farmacia Hospital Universitario Miguel Servet HUMS

@FarmaciaHums · X

Jan 19, 2021 · 3 likes · 3 shares · 794 followers View post →

Miguelandry Perez

@DrMiguelandry · X

Disponible en: https://t.co/YNgNOkxBvZ #medicinainterna #MedicinaCritica #diabetesmellitus #Cardiologia #drmiguelandry @MedicoTactico @dracortezm @ivonderosten https://t.co/PVwZEcJbYS

Jan 18, 2021 · 2 likes · 561 followers View post →

Last Week in Medicine

@lastweekinmed · X

In patients with DM and CKD, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from CV causes, hospitalizations for HF, and urgent visits for HF than placebo but was associated with more adverse events. @NEJM https://t.co/BygCmi6i25

Jan 17, 2021 · 867 followers View post →

Mushfiquzzaman

@Mushfiq_16 · X

In patients with diabetes and CKD, with/without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. https://t.co/Qx7bECZ5Uw

Jan 17, 2021 · 167 followers View post →

Tá de Clinicagem - TdC

@tadeclinicagem · X

O primeiro trial, SCORED, randomizou 10.584 pcts com DM2 e DRC (TFG 25 a 60), e encontrou redução de desfecho cardiovascular! E independente do valor da albuminúria! Os efeitos adversos foram similares aos outros iSTLG2 (CAD, hipovolemia, ITU e diarreia) https://t.co/IM4jgIkWBY

Jan 16, 2021 · 3 likes · 12,009 followers View post →

Mamas A. Mamas

@mmamas1973 · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 16, 2021 · 13 shares · 79,740 followers View post →

Italo Kumamoto

@fikkumamoto · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 16, 2021 · 13 shares · 8,811 followers View post →

Vass Vassiliou

@vass_vassiliou · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 10,181 followers View post →

Rodney Samaan

@rsamaan · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 2,381 followers View post →

Carlos G Santos-Gallego, MD

@SantosGallegoMD · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 2,468 followers View post →

John P Erwin III MD MBA MACC (#BigPoppy )

@HeartOTXHeartMD · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 39,644 followers View post →

Andrew J Sauer MD

@AndrewJSauer · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 19,212 followers View post →

Anju Bhardwaj MD FACC

@docbhardwaj · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 4,509 followers View post →

Dr.Rajiv Sankaranarayanan

@DrRajivsankar · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 3,990 followers View post →

fozia ahmed

@foziaahmedMD · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 1,116 followers View post →

Ekaterini Lambrinou

@EkateriniL · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 3,388 followers View post →

Sohail Khan MD,MHCM

@SKhanMHCM · X

RT @hvanspall: Delighted to discuss the #SCORED RCT (published in @NEJM this week) with @DLBHATTMD In #DM + #CKD, #sotagliflozin: ⬇️risk o…

Jan 15, 2021 · 13 shares · 4,159 followers View post →

Harriette Van Spall, MD MPH

@hvanspall · X

Jan 15, 2021 · 30 likes · 13 shares · 17,791 followers View post →

Telaraña Farmacéutica

@telarfarma · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 15, 2021 · 43 shares · 1,442 followers View post →

tim worthen

@tmworthen · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 15, 2021 · 43 shares · 121 followers View post →

Sarah Sattin

@SarahSattin_ · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 15, 2021 · 43 shares · 745 followers View post →

river_invest

@ZickZac38101915 · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 15, 2021 · 43 shares · 14 followers View post →

Sirona Biochem

@SironaBiochem · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 15, 2021 · 43 shares · 1,372 followers View post →

Schakamann

@schakamann · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 21 followers View post →

Linda

@wordfinga · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 4,597 followers View post →

Shelley Zieroth

@ShelleyZieroth · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 9,984 followers View post →

Charles Cardone

@CharlesCardone · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 79 followers View post →

Alex Kharlamov MD FESC FACC FEACVI

@drskharlamov · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 1,673 followers View post →

Sneha Shah Jain, MD, MBA

@SnehaShahJain · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 1,008 followers View post →

Poonam Velagapudi

@Pooh_Velagapudi · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 11,710 followers View post →

Joel "Heart Prevention" Kahn MD, FACC

@drjkahn · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 32,293 followers View post →

Dr. Martha Gulati ♥️

@DrMarthaGulati · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 64,633 followers View post →

Samuel Moisén Bello

@BelloMoisen · X

RT @AmbrizMau: En pacientes con diabetes y ERC con o sin albuminuria, SOTAGLIFLOZINA resultó en menor riesgo de muertes por causas cardiova…

Jan 14, 2021 · 12 shares · 32 followers View post →

Vademon24292

@CarlosA09557330 · X

RT @AmbrizMau: En pacientes con diabetes y ERC con o sin albuminuria, SOTAGLIFLOZINA resultó en menor riesgo de muertes por causas cardiova…

Jan 14, 2021 · 12 shares · 519 followers View post →

Abdallah Al-Mohammad

@AAlMohammad87 · X

RT @BSHeartFailure: In DM+CKD, sotagliflozin reduces CV deaths + HF hospital but at cost of diarrhoea particularly. N Engl J Med 2021 DOI:…

Jan 14, 2021 · 2 shares · 924 followers View post →

Annette Bruchfeld

@AnnetteBruchfe1 · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 2,291 followers View post →

J. Airton Arruda

@jairtonarruda · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 2,771 followers View post →

Chih

@ChihWong · X

RT @BSHeartFailure: In DM+CKD, sotagliflozin reduces CV deaths + HF hospital but at cost of diarrhoea particularly. N Engl J Med 2021 DOI:…

Jan 14, 2021 · 2 shares · 459 followers View post →

Salvador Terán

@teranmed · X

1/5 ✅Sotaglifozina

Jan 14, 2021 · 1 like · 124 followers View post →

Taha Ahmed, MD, MS

@TahaAhmedMD · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 1,102 followers View post →

fozia ahmed

@foziaahmedMD · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 1,116 followers View post →

Juanmarcosgg

@juanmarcosgg · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 510 followers View post →

Regina Dalmau

@reginadalmau · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 4,459 followers View post →

Stephen Voyce

@SJVNEPA · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 858 followers View post →

Amir Darki MD, MSc

@darki_amir · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 727 followers View post →

DocJuanUbaldo

@DocUbaldo · X

RT @AmbrizMau: En pacientes con diabetes y ERC con o sin albuminuria, SOTAGLIFLOZINA resultó en menor riesgo de muertes por causas cardiova…

Jan 14, 2021 · 12 shares · 3,197 followers View post →

José Pérez Silvestre

@jopesilver · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 832 followers View post →

Anu Lala (Anuradha Lala-Trindade)

@dranulala · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 12,834 followers View post →

Seigo Izumo

@SeigoIzumo · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 3,968 followers View post →

Holly Kramer, MD, MPH

@kramer_holly · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 4,050 followers View post →

Manish Mehta

@kenyamanish · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 153 followers View post →

Hany Ragy

@Hragy · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 80,367 followers View post →

John P Erwin III MD MBA MACC (#BigPoppy )

@HeartOTXHeartMD · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 39,644 followers View post →

Vineet Sankhla

@vineetcardio · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 1,406 followers View post →

Jose Carlos Arevalo

@joscarlor2 · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 756 followers View post →

Aisha Shaikh

@aishaikh · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 8,641 followers View post →

Pradeep Natarajan

@pnatarajanmd · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 25,299 followers View post →

Muthu Vaduganathan

@mvaduganathan · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 9,130 followers View post →

Alejandro Martínez Gallardo

@dr_alejandromg · X

Estudio SCORED, uso de Sotaglifozina en pacientes con DM2 y ERC (TFG 25-60 ml/min/1.73m2) -Desenlaces primarios (muerte, falla cardiaca): 5.6 / 100 vs 7.5/100 pacientes (HR 0.74; 95% CI 0.63-0.88; P<0.001). -Más efectos adversos con Sotaglifozina. DOI:10.1056/NEJMoa2030186 https://t.co/J8vmFpGDEo

Jan 14, 2021 · 1 like · 1,719 followers View post →

Timir Paul, MD, PhD, FACC, FSCAI, FAHA

@timir_paul · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 6,214 followers View post →

Marcos Benitez

@Quito_mb · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 348 followers View post →

Edwindelap

@edwindelap · X

RT @AmbrizMau: En pacientes con diabetes y ERC con o sin albuminuria, SOTAGLIFLOZINA resultó en menor riesgo de muertes por causas cardiova…

Jan 14, 2021 · 12 shares · 82 followers View post →

British Society for Heart Failure #theFword

@BSHeartFailure · X

In DM+CKD, sotagliflozin reduces CV deaths + HF hospital but at cost of diarrhoea particularly. N Engl J Med 2021 DOI: 10.1056/NEJMoa2030186

Jan 14, 2021 · 7 likes · 2 shares · 11,450 followers View post →

Sundeep Chaudhry

@ChaudhrySundeep · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 181 followers View post →

José R. Straga Zué

@jstragazue · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 1,584 followers View post →

Najdat Bazarbashi نجدت بازارباشي

@NajdatB1 · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 740 followers View post →

Tor Biering-Sørensen, MD, MSc, MPH, PhD

@TorBiering · X

RT @DLBHATTMD: SCORED now published in print in @NEJM - benefits of SGLT2 inhibition in diabetes plus chronic kidney disease. And showing r…

Jan 14, 2021 · 43 shares · 1,343 followers View post →

Dr. Deepak L. Bhatt

@DLBHATTMD · X

Jan 14, 2021 · 159 likes · 43 shares · 39,830 followers View post →

Sebastián Tenorio Vargas

@SebasTenorio · X

RT @AmbrizMau: En pacientes con diabetes y ERC con o sin albuminuria, SOTAGLIFLOZINA resultó en menor riesgo de muertes por causas cardiova…

Jan 14, 2021 · 12 shares · 536 followers View post →

Asociación Cardiología Clínica SEC

@clinica_sec · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 6,599 followers View post →

Cardiología Preventiva

@preventiva_SEC · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 2,440 followers View post →

Muhammad Tahir

@tauhair · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 242 followers View post →

Juan Carlos Obaya

@jcobaya69 · X

RT @DanielJDrucker: And the second trial for sotagliflozin published today, showing benefit in PPL with #T2D #CKD @DLBHATTMD https://t.co/6…

Jan 14, 2021 · 2 shares · 856 followers View post →

Eduardo Salas

@coteyayo · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 128 followers View post →

Nicolas Manito

@Dr_Manito · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 5,471 followers View post →

@investigando

@rocatanho · X

En pacientes con diabetes y nefropatía crónica, sotaglifozina reduciría el riesgo de muerte por causas CV, y hospitalizaciones y visitas a urgencia por insuficiencia cardíaca pero se asociaría con eventos adversos https://t.co/YwNGcEqubr

Jan 14, 2021 · 400 followers View post →

✨

@DraPettite · X

RT @AmbrizMau: En pacientes con diabetes y ERC con o sin albuminuria, SOTAGLIFLOZINA resultó en menor riesgo de muertes por causas cardiova…

Jan 14, 2021 · 12 shares · 1,408 followers View post →

Dr. Michael Alexander

@MichaelAlexandp · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 831 followers View post →

Vicente Arrarte

@varrarte · X

RT @JTLLERGO: ⚠️Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ‼️ DM2+CKD, with or without albuminuria, sotagliflozin➡️…

Jan 14, 2021 · 10 shares · 3,580 followers View post →

shahin mohammed

@shahsonride · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/aNvvLyhUwE

Dec 9, 2020 · 1 like · 495 followers View post →

Charu Malik

@CharuMalik_ISN · X

RT @ISNeducation: SCORED trial : Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Albuminuria is not related to outcome…

Dec 9, 2020 · 3 shares · 1,167 followers View post →

Brendan

@brendanjsmyth · X

RT @ISNeducation: SCORED trial : Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Albuminuria is not related to outcome…

Dec 9, 2020 · 3 shares · 140 followers View post →

Abdelhamid Hamdy

@abdelhamed012 · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/rhoUdJcPBZ

Dec 9, 2020 · 3,304 followers View post →

Dr Theepa N.M.R

@TNesam · X

RT @ISNeducation: SCORED trial : Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Albuminuria is not related to outcome…

Dec 9, 2020 · 3 shares · 697 followers View post →

ISN Education

@ISNeducation · X

SCORED trial : Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Albuminuria is not related to outcome but be careful with adverse events @didemturgut_ @ISNkidneycare @NEJM #ISNyoung #CKD

Dec 9, 2020 · 1 like · 3 shares · 10,465 followers View post →

Tal Givoly

@givoly · X

RT @aussiecoley: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/JZ4zUIkzEp

Dec 8, 2020 · 1 share · 2,652 followers View post →

noel cole

@aussiecoley · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/JZ4zUIkzEp

Dec 8, 2020 · 1 share · 787 followers View post →

青島周一

@syuichiao89 · X

ソタグリフロジン

Dec 3, 2020 · 8,602 followers View post →

青島周一

@syuichiao89 · X

#未読 https://t.co/ZJtUhDTOvc https://t.co/83MNL4omDU https://t.co/0L0lSTVqvD https://t.co/9Wj7wGOAGl https://t.co/1lWyRYmW1J https://t.co/uuD8VrYduS https://t.co/v89kjFaqw1 https://t.co/dTYQL6JaSJ https://t.co/f97vtpXKRH https://t.co/3U6Gdw3PNd

Dec 1, 2020 · 3 likes · 8,602 followers View post →

横山暁子

@yokoakipp · X

RT @makotoura: N Engl J Med. 2020 Nov 16. またソタグリフロジン。患者は糖尿病＋慢性腎臓病G3~4。心血管系の原因による死亡、心不全による入院、心不全の緊急訪問の複合リスクが低い。またsotaが勝ってしまったか。 https://t.co…

Nov 27, 2020 · 3 shares · 1,116 followers View post →

Miya

@HiromiMiyamoto3 · X

Nov 27, 2020 · 3 shares · 922 followers View post →

青島周一

@syuichiao89 · X

Nov 27, 2020 · 3 shares · 8,602 followers View post →

大浦誠

@makotoura · X

Nov 27, 2020 · 17 likes · 3 shares · 12,963 followers View post →

Patrick O. Gee, Ph.D. JLC

@PGee51 · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/QEnmOey0kz

Nov 25, 2020 · 894 followers View post →

pinacol

@pinacol · X

【RCT】CKDおよび心血管疾患リスクを伴う2型糖尿病患者へのSotagliflozin投与は、プラセボ投与と比較して、心血管死、心不全による入院および心不全による緊急受診を減少させた（主要評価項目を試験中に変更; 資金の喪失により早期終了）。 #ペ読 https://t.co/RfDHRCE0yL

Nov 22, 2020 · 2 likes · 1 share · 1,612 followers View post →

Tom

@youareinformed · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. https://t.co/YY4FldETdU

Nov 19, 2020 · 3,278 followers View post →

the paper link

@the_paper_link · X

RT @the_paper_link: Trend new: **Bhatt DL** et al (N Engl J Med) __Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease__ htt…

Nov 19, 2020 · 1 share · 137 followers View post →

Med Peds Hospitalist

@medpedshosp · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dHOl8RHABr

Nov 18, 2020 · 1 like · 14,199 followers View post →

the paper link

@the_paper_link · X

Trend new: **Bhatt DL** et al (N Engl J Med) __Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease__ https://t.co/duJZSgoJIX

Nov 18, 2020 · 1 share · 137 followers View post →

renalRCTs

@renalRCTs · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. https://t.co/YNRZhqqaS9 https://t.co/DjMIeHhRcf

Nov 18, 2020 · 1 like · 39 followers View post →

Annals of Cardiovascular and Thoracic Surgery

@AndThoracic · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 18, 2020 · 14 shares · 290 followers View post →

hanis hanum zulkifly

@hanishanum · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 18, 2020 · 14 shares · 85 followers View post →

هِـنـد الـمَـانِـع

@HindAlmanea · X

RT @Pharmaxp: #Sotagliflozin in Patients with #Diabetes and Chronic #Kidney Disease https://t.co/WbWBmEZUXb

Nov 18, 2020 · 1 share · 61 followers View post →

Ozlem Bilen MD

@ozlembilen2 · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 3,409 followers View post →

Ayshwarya Subramanian

@ayshwaryas · X

RT @KSusztak: Your regular reminder on the benefits of SGLTi and kidney disease | SCORED | Sotagliflozin in Patients with Diabetes and Chro…

Nov 17, 2020 · 1 share · 1,156 followers View post →

Alison L. Bailey, MD

@a_l_bailey · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 5,277 followers View post →

Katalin Susztak

@KSusztak · X

Your regular reminder on the benefits of SGLTi and kidney disease | SCORED | Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | @NEJM https://t.co/6dwDHKhG3Q Keep coming...

Nov 17, 2020 · 17 likes · 1 share · 6,993 followers View post →

Joanna Lis

@JoannnaLis · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 912 followers View post →

Prof Kamlesh Khunti

@kamleshkhunti · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 24,422 followers View post →

Dr. Luiz Silva

@DrLuizSilva1 · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 392 followers View post →

Stefania Arciello

@StefaniaArciell · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/cC281mCBtD

Nov 17, 2020 · 2 likes · 1,946 followers View post →

Farooq Rafique

@rafique_farooq · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/RwovOUwV5u

Nov 17, 2020 · 34 followers View post →

Adam Potter, MD, PhD, FACC

@AdamPotterMDPhD · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/O7RDiQgOXJ

Nov 17, 2020 · 426 followers View post →

Mark Petrie

@markcpetrie20 · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 1,283 followers View post →

Sinead Hughes

@SineadHughes19 · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 1,673 followers View post →

Prof Derek Connolly

@DrDerekConnolly · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 3,932 followers View post →

Baronian Consulting

@BaronianConsult · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/waUZXj3Hou

Nov 17, 2020 · 1,090 followers View post →

Dr Muhammad Avais

@mian_avais · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 114 followers View post →

Dimitris Papamargaritis

@ri_tis · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 698 followers View post →

Dr Thurairajah

@RubenThurairaj · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 3,658 followers View post →

Pradeep Natarajan

@pnatarajanmd · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 25,299 followers View post →

Department of Primary Care & Public Health

@Imperial_PCPH · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 2,221 followers View post →

Cliff Dominy

@CliffDominy · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 385 followers View post →

Elaine Jennings

@Elainejenning14 · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 883 followers View post →

名前

@akkiii0830 · X

なんか別の試験も出ているな https://t.co/UaZNI39u1G Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Nov 17, 2020 · 246 followers View post →

Ritu Thamman MD

@iamritu · X

RT @ALEX_MISCHIE: #AHA20 Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease @AHAMeetings @NEJM https://t.co/DCcIA2olie #…

Nov 17, 2020 · 2 shares · 31,641 followers View post →

د. محمد فودة

@Pharmaxp · X

#Sotagliflozin in Patients with #Diabetes and Chronic #Kidney Disease https://t.co/WbWBmEZUXb

Nov 17, 2020 · 2 likes · 1 share · 1,684 followers View post →

Dr. Hellena Hailu Habte-Asres

@HellenaHH2020 · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 506 followers View post →

Mihai Trofenciuc

@MihaiTrofenciuc · X

RT @ALEX_MISCHIE: #AHA20 Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease @AHAMeetings @NEJM https://t.co/DCcIA2olie #…

Nov 17, 2020 · 2 shares · 3,873 followers View post →

Kamol

@KamolMU · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 101 followers View post →

EASDelearning

@EASDelearning · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 5,268 followers View post →

Abd Tahrani

@AbdTahrani · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 7,584 followers View post →

Gaurav Gulsin

@GauravGulsin · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 802 followers View post →

Kevin Fernando

@drkevinfernando · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 5,132 followers View post →

Ines Fonseca

@Ines_VFonseca · X

RT @AmarPut: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again…

Nov 17, 2020 · 11 shares · 919 followers View post →

EndoNutr-HClinUValencia

@endonutrHCUVal · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM también beneficios renales ⁦@SVEDYN_⁩ ⁦@jlgorriz⁩ ⁦@Raquelsegpor⁩ https://t.co/ZvS74ukLkH

Nov 17, 2020 · 1 like · 604 followers View post →

Dr Amar Puttanna

@AmarPut · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/dmbAqEvqbU SGLT2s have SCORED again

Nov 17, 2020 · 24 likes · 11 shares · 3,615 followers View post →

ALEXANDRU MISCHIE

@ALEX_MISCHIE · X

#AHA20 Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease @AHAMeetings @NEJM https://t.co/DCcIA2olie #cardiotwitter @bogdan_popescu1 @ShelleyZieroth @Hragy @aayshacader @FZores @gregoirerange @biljana_parapid @nicolasamabile @pcommeau @iamritu

Nov 17, 2020 · 10 likes · 2 shares · 10,325 followers View post →

Francesc Formiga

@FormigaFrancesc · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/0kuueS091Q

Nov 17, 2020 · 1,940 followers View post →

Dr. Deepak L. Bhatt

@DLBHATTMD · X

RT @ProfKausikRay: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM. Overwhelming data now for SGLT2i . Delighted…

Nov 17, 2020 · 14 shares · 39,830 followers View post →

Prof Kausik Ray FMedSci

@ProfKausikRay · X

Nov 17, 2020 · 66 likes · 14 shares · 5,966 followers View post →

خالد القرني

@DrKhaledAlqarni · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/Nzdji9ITKD

Nov 16, 2020 · 2 likes · 1,320 followers View post →

Ph.Gabriel Steg

@gabrielsteg · X

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | NEJM https://t.co/vH0s34hDJV

Nov 16, 2020 · 2 likes · 2,951 followers View post →

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor for Diabetes and Kidney Disease

Exploring Longevity: Supplements, Drug Repurposing, and CR Insights

Sotagliflozin: Dual SGLT Inhibitor for Diabetes Management

Insights into Subclinical Atrial Fibrillation Progression and Detection